LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, shares results from a newly published clinical study, as reported in the peer-reviewed journal Cell Reports, demonstrating that supplementation with nicotinamide riboside (NR), one of the most efficient and superior NAD+ precursors, reduced inflammation in both healthy subjects and in cells derived from psoriasis patients.

洛杉矶-（商业时报）-ChromaDex Corp.（纳斯达克股票代码：CDXC），一家烟酰胺腺嘌呤二核苷酸（NAD+）研究和健康老龄化的全球权威机构，分享了一项新发表的临床研究的结果，同行评审的期刊Cell Reports，证明补充烟酰胺核苷（NR），最有效和最优越的NAD+前体之一，减少健康受试者和源自牛皮癣患者的细胞中的炎症。

The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicotinamide riboside (NR) ingredient, Niagen, for the advancement of this research..

临床试验是ChromaDex外部研究项目（CERP）的一部分™), 捐赠了ChromaDex专利的烟酰胺核苷（NR）成分Niagen，用于推进这项研究。。

“We express our gratitude to Dr. Michael Sack, Senior Investigator of Mitochondrial Biology and Metabolism at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), for his exceptional contributions with this research. This is Dr. Sack’s fourth published study on NR, and the seventh clinical study overall, that demonstrates NR’s effectiveness in reducing inflammation, an important indicator of how the body is aging,” remarked Rob Fried, CEO of ChromaDex.

“我们感谢美国国立卫生研究院（NIH）国家心肺血液研究所（NHLBI）线粒体生物学和代谢高级研究员Michael Sack博士对本研究的杰出贡献。这是博士。Sack的第四篇关于NR的研究和第七项临床研究总体上证明了NR在减少炎症方面的有效性，炎症是身体衰老的重要指标，“ChromaDex首席执行官Rob Fried说。

“In addition to a balanced diet and regular exercise, elevating NAD+ levels with Tru Niagen remains the safest, most effective, legally protected, and extensively researched NAD+ dietary supplement that helps us age better. This research is a testament to why ChromaDex continues to be the gold standard in the rapidly expanding NAD+ space.”.

“除了均衡饮食和定期锻炼外，使用Tru Niagen提高NAD+水平仍然是最安全，最有效，受法律保护和广泛研究的NAD+膳食补充剂，可帮助我们更好地衰老。这项研究证明了为什么ChromaDex继续成为快速扩展的NAD+空间的黄金标准“。

An evolution in NAD+ research, this study builds on a growing body of evidence suggesting that NR defends against inflammation not only in individuals who are elderly or have inflammation-related disease, as they are associated with lower levels of NAD+ and higher inflammation markers, but may also provide anti-inflammatory benefits for healthy individuals.

NAD+研究的进展，这项研究建立在越来越多的证据基础上，这些证据表明NR不仅可以防御老年人或患有炎症相关疾病的个体的炎症，因为它们与较低水平的NAD+和较高的炎症标志物相关，但也可能为健康人提供抗炎益处。

This is the third published human clinical study demonstrating that NR supplementation has a protective effect in healthy individuals and lays the foundation for future clinical research (Elhassan et al. 2019, Remie et al. 2020)..

这是第三篇发表的人体临床研究，证明补充NR对健康个体具有保护作用，并为未来的临床研究奠定了基础（Elhassan等，2019；Remie等，2020）。。

The connection between NAD+ and inflammation

NAD+与炎症之间的联系

Underlying chronic inflammation, also known as metaflammation or inflammaging, appears to be a consistent factor in ailing populations, in illness associated with age-related decline, and even in relatively healthy individuals, and has been linked to the development of autoimmune disorders, such as psoriasis and lupus, and chronic diseases, such as diabetes, cardiovascular disease, Alzheimer’s disease, Parkinson’s disease, among others.

潜在的慢性炎症，也称为metaflammation或炎症，似乎是疾病人群，与年龄相关的衰退相关的疾病，甚至是相对健康的个体中的一致因素，并且与自身免疫性疾病的发展有关，例如牛皮癣和狼疮，以及慢性疾病，如糖尿病，心血管疾病，阿尔茨海默病，帕金森病等。

Research has demonstrated environmental and lifestyle factors such as smoking, poor diet, lack of exercise, and sleep deprivation can contribute to states of chronic underlying inflammation..

研究表明，环境和生活方式因素，如吸烟，不良饮食，缺乏运动和睡眠不足可能导致慢性潜在炎症状态。。

NAD+ is a critical coenzyme for all living cells and maintaining intracellular NAD+ pools is critical in supporting cellular and metabolic processes, including adenosine triphosphate (ATP) production (the source of cellular energy) and DNA repair. Research suggests a depletion of NAD+ is associated with impaired inflammatory responses and innate immune dysfunction, indicating NAD+ levels may have a critical impact on the function of immune cells..

NAD+是所有活细胞的关键辅酶，维持细胞内NAD+库对于支持细胞和代谢过程至关重要，包括三磷酸腺苷（ATP）产生（细胞能量来源）和DNA修复。研究表明，NAD+的消耗与炎症反应受损和先天性免疫功能障碍有关，表明NAD+水平可能对免疫细胞的功能产生关键影响。。

Research supporting anti-inflammatory effects of NR, the most efficient NAD+ precursor

研究支持最有效的NAD+前体NR的抗炎作用

NR is one of the most efficient and superior NAD+ precursors, clinically proven to increase NAD+ safely and effectively. There is an ever-growing body of clinical evidence demonstrating the anti-inflammatory effects of NR supplementation (either alone or in combination with other ingredients) for healthy, older adults, or those with inflammation-related disorders, with potential for more robust effects among the elderly and diseased populations as they tend to have compromised NAD+ and a higher inflammatory status.

NR是最有效和最优越的NAD+前体之一，临床证明可以安全有效地增加NAD+。越来越多的临床证据表明NR补充剂（单独或与其他成分组合）对健康，老年人或炎症相关疾病患者的抗炎作用，可能产生更强的作用。老年人和患病人群，因为他们倾向于损害NAD+和更高的炎症状态。

These studies are outlined in table 1..

这些研究概述在表1中。。

TABLE 1. Summary of peer-reviewed, published NR studies demonstrating an anti-inflammatory effect in humans.

表格1。同行评审，发表的NR研究总结，证明了对人类的抗炎作用。

NICOTINAMIDE RIBOSIDE ONLY

仅烟酰胺核苷

Publication

出版物

Dose/Duration

剂量/持续时间

Study Population

研究人群

Key Results

关键结果

Elhassan et al., 2019

Elhassan等人，2019

1,000 mg/day for 21 days

1000毫克/天，连续21天

Marginally overweight, but otherwise healthy older adult men

略微超重，但健康的成年男性

NR reduced levels of circulating inflammatory cytokines IL-6, IL-5, IL-2, and TNF-α

NR降低循环炎性细胞因子IL-6，IL-5，IL-2和TNF-α的水平

Zhou et al., 2020

周等人，2020

1,000 mg/day for 5-9 days

1000毫克/天，5-9天

Hospitalized patients with stage D heart failure undergoing advanced heart failure therapy evaluations

D期心力衰竭住院患者接受晚期心力衰竭治疗评估

NR reduced gene expression of NLRP3 and inflammatory cytokines (IL-1B, IL-6, and IL-18)

NR降低NLRP3和炎性细胞因子（IL-1B，IL-6和IL-18）的基因表达

Remie et al., 2020

Remie等人，2020年

1,000 mg/day for 6 weeks

1000毫克/天，连续6周

Healthy overweight and obese men and postmenopausal women

健康超重和肥胖男性和绝经后妇女

NR resulted in a significant trend toward a reduction in plasma IL-1α levels

NR导致血浆IL-1水平显著降低

Wu et al., 2022

吴等人，2022

1,000 mg/day for one week

1000毫克/天，一周

Young healthy subjects and patients with systemic lupus erythematosus (SLE)

年轻健康受试者和系统性红斑狼疮（SLE）患者

NR reduced relative mRNA expressions of inflammatory cytokines IFN-β and CXCL10

NR降低炎性细胞因子IFN-β和CXCL10的相对mRNA表达

Brakedal et al., 2022

Brakedal等人，2022

1,000 mg/day for 4 weeks

1000毫克/天，连续4周

Newly diagnosed dopaminergic therapy-naïve Parkinson’s disease patients

新诊断的多巴胺能治疗初治帕金森病患者

NR reduced levels of inflammatory cytokines in the serum: VEGF and GDF15, as well as in cerebrospinal fluid: G-CSF, IL-7, IL-1RA, CCL4

NR降低了血清中炎性细胞因子的水平：VEGF和GDF15，以及脑嵴液：G-CSF，IL-7，IL-1RA，CCL4

Wang et al., 2022

王等，2022

2,000 mg/day for 12 weeks

2000毫克/天，持续12周

Stage C heart failure with reduced ejection fraction patients and age-matched healthy subjects

C期心力衰竭伴射血分数降低的患者和年龄匹配的健康受试者

NR reduced expression of NLRP3 and resulted in directionally similar, though nonsignificant, changes in expression of other inflammatory markers (IL-1B, IL-6, IL-18, and TNF-α) [AH1]

NR降低NLRP3的表达，并导致其他炎症标志物（IL-1B，IL-6，IL-18和TNF-α）[AH1]表达的方向相似但无显着变化

Han et al., 2023

韩等人，2023

1,000 mg/day for 1 week

1000毫克/天，持续1周

Young, healthy subjects

年轻健康的科目

NR blunted TH1 and TH17 immune cell responsiveness and depressed the secretion of IFNγ and IL-17 in CD4+ T cells

NR减弱TH1和TH17免疫细胞反应性并抑制CD4+T细胞中IFNγ和IL-17的分泌

NICOTINAMIDE RIBOSIDE IN COMBINATION WITH OTHER INGREDIENTS

烟酰胺核苷与其他成分的组合

Zeybel et al., 2022

Zeybel等人，2022年

CMA*

CMA*

Nonalcoholic fatty liver disease (NAFLD) patients

非酒精性脂肪性肝病（NAFLD）患者

CMA decreased levels of inflammatory cytokines CD-8A, CCL23, FGF-21, and oncostatin-M (OSM)

CMA降低炎性细胞因子CD-8A，CCL23，FGF-21和制瘤素-M（OSM）的水平

Altay et al., 2021

阿尔泰等人，2021

CMA*

CMA*

Ambulatory COVID-19 patients

门诊COVID-19患者

CMA decreased levels of inflammatory cytokines CSF-1, IL-15RA, IL-18, MCP-1, and TNF-α

CMA降低炎性细胞因子CSF-1，IL-15RA，IL-18，MCP-1和TNF-α的水平

About the study

关于这项研究

The first part of this clinical study analyzed the effects of ex-vivo (outside of the living organism) NR supplementation on adaptive immunity in CD4+ T cells, which play a vital role in regulating effective immune response to pathogens. CD4+ T cells were extracted from patients with mild-moderate psoriasis and age and gender-matched healthy controls (average age of 48).

本临床研究的第一部分分析了离体（生物体外）NR补充对CD4+T细胞适应性免疫的影响，CD4+T细胞在调节对病原体的有效免疫应答中起着至关重要的作用。从轻度-中度银屑病患者和年龄和性别匹配的健康对照（平均年龄48岁）中提取CD4+T细胞。

The second part of the study analyzed the effects of oral NR supplementation on primary CD4+ T cell function using samples obtained from a prior pilot, randomized, double-blinded, placebo-controlled study in which 25 healthy subjects (average age of 24 and average BMI of 23) were supplemented with 1000mg NR or placebo daily for 7 days (Wu et al., 2022)..

该研究的第二部分使用从先前的试验，随机，双盲，安慰剂对照研究获得的样品分析口服NR补充对原代CD4+T细胞功能的影响，其中25名健康受试者（平均年龄24岁和平均年龄）BMI为23）每天补充1000mg NR或安慰剂7天（Wu等，2022）。。

Study highlights

研究亮点

Ex vivo NR supplementation in CD4+ T cells in both healthy volunteers and patients with mild-moderate psoriasis reduced TH1 and TH17 immune responsiveness, characteristic features in psoriasis, and depressed the secretion of IFNγ and IL-17 (pro-inflammatory factors observed in autoimmune disorders that contribute to overactive CD4+ T cells)..

在健康志愿者和轻度-中度银屑病患者中CD4+T细胞的离体NR补充降低了TH1和TH17免疫应答性，银屑病的特征性特征，并抑制了IFNγ和IL-17的分泌（在自身免疫中观察到的促炎因子导致CD4+T细胞过度活跃的疾病）。。

Genes related to antioxidant defense pathways were upregulated in CD4+ T cells in response to NR treatment.

响应于NR处理，与抗氧化防御途径相关的基因在CD4+T细胞中上调。

NR decreased the production and activity of harmful reactive oxygen species (which causes damage to the building blocks of the cell including DNA), and reduced lipid peroxidation (a process by which oxidants attack healthy lipids, resulting in cell death) in CD4+ T cells.

NR降低了CD4+T细胞中有害活性氧的产生和活性（导致包括DNA在内的细胞结构单元受损），并降低了脂质过氧化（氧化剂攻击健康脂质的过程，导致细胞死亡）。

Psoriatic T cells demonstrated both a reduction of NAD+ and upregulation of NAD+ consuming enzymes, as compared to the cells extracted from healthy individuals. These data suggest that psoriasis amplifies NAD+ consumption and that boosting NAD+ levels is necessary to blunt TH17 immune cell responsiveness..

与从健康个体提取的细胞相比，银屑病T细胞表现出NAD+的减少和NAD+消耗酶的上调。这些数据表明，牛皮癣放大NAD+消耗，并且提高NAD+水平对于钝化TH17免疫细胞反应性是必需的。。

In the in-vivo analysis, oral NR supplementation in healthy participants reflected the immune-modulating effects of ex-vivo NR supplementation. More specifically, oral NR reduced inflammatory biomarkers and enhanced antioxidant gene expression in immune cells.

在体内分析中，健康参与者的口服NR补充剂反映了离体NR补充剂的免疫调节作用。更具体地说，口服NR减少炎症生物标志物并增强免疫细胞中的抗氧化基因表达。

Relevance

关联

Due to the success of data collected from both studies led by Dr. Sack, Han et al., 2023 and Wu et al., 2022, the effects of NR supplementation in mild-moderate psoriasis patients are currently being explored by the investigators in an in vivo placebo-controlled clinical trial. The findings from this study builds on a growing body of evidence suggesting that increasing NAD+ levels with NR supplementation not only defends against inflammation for healthy individuals, but also suggests a potential therapeutic application for individuals with autoimmune disorders, such as psoriasis, pending further research confirmation..

由于从Sack博士，Han等人，2023和Wu等人，2022领导的两项研究中收集的数据的成功，研究人员目前正在探索NR补充对轻度-中度银屑病患者的影响。体内安慰剂对照临床试验。这项研究的结果建立在越来越多的证据基础上，这些证据表明补充NR可以增加NAD+水平，不仅可以预防健康个体的炎症，还可以为患有自身免疫性疾病（如牛皮癣）的个体提供潜在的治疗应用，等待进一步研究确认。。

For additional information on ChromaDex, visit www.chromadex.com.

有关ChromaDex的更多信息，请访问www.ChromaDex.com。

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this press release was supported by the Mitochondrial Biology and Metabolism, National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health under award number ZIA-HL005102..

免责声明：内容完全是作者的责任，不一定代表国立卫生研究院的官方观点。本新闻稿中报道的研究得到了美国国立卫生研究院国家心肺血液研究所（NHLBI）线粒体生物学和代谢的支持，奖项编号为ZIA-HL005102。。

About ChromaDex:

关于ChromaDex：

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®.

ChromaDex Corp.是一家致力于健康老龄化的全球生物科学公司。包括世界知名科学家在内的ChromaDex团队正在对烟酰胺腺嘌呤二核苷酸（NAD+）进行开创性研究，其水平随着年龄的增长而下降。ChromaDex是NAD+前体烟酰胺核苷（NR）的创新者，作为旗舰成分Niagen®商业化。

Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company..

烟酰胺核苷和其他NAD+前体受ChromaDex专利组合的保护。ChromaDex在www.ChromaDex.com维护一个网站，ChromaDex定期向该网站发布其新闻稿的副本以及有关该公司的其他财务信息。。

Forward-Looking Statements:

前瞻性声明：

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to whether these findings contribute to the mounting evidence indicating that NR may serve as a proactive safeguard against inflammatory cytokines in healthy adults and those with inflammation-related disorders.

本版本包含1933年“证券法”第27A条（经修订）和1934年“证券交易法”第21E条（经修订）含义内的前瞻性声明，包括关于这些发现是否有助于越来越多的证据表明NR可以作为健康成人和炎症相关疾病患者的炎性细胞因子的主动保护措施的陈述。

Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'could' or the negative of such terms or other similar expressions.

不是对历史事实的描述的陈述构成前瞻性陈述，并且通常（但不总是）可以通过使用诸如“期望”，“预期”，“意图”，“估计”，“计划，“潜力”，“可能”，“可能”，“相信”，“寻求”，“可能”，“将会”，“应该”或这些术语或其他类似表达的否定。

Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition.

导致这些前瞻性声明性质不确定的风险包括COVID-19大流行对我们业务和全球经济的影响；我们的经营损失历史和需要获得额外融资；我们产品销售的增长和盈利能力；我们保持销售，营销和分销能力的能力；改变消费者对我们产品的看法；我们依赖单一或有限数量的第三方供应商；以及与我们的业务和财务状况相关的风险和不确定性。

More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov.

有关ChromaDex的更详细信息以及可能影响实现前瞻性报表的风险因素，请参阅ChromaDex在截至2022年12月31日的财政年度10-K表格年度报告，ChromaDex关于表格10-Q的季度报告和ChromaDex向SEC提交的其他文件，其副本可从SEC网站www.SEC.gov获取。

Readers are cautioned not .

读者不要。